Ann: Positive DEP Cabazitaxel Phase 2 Results in Multiple Cancer, page-61

I have never said they won't license it and I have given my estimates previously (back in 2022 when @antibotter claimed we would get $100 million for each DEP® drug - see below post) ..... I don't think Sanofi will license DEP® Cabazitaxel but they might try and stop its progress knowing Starpharma don't have the funds to fight them in court so without big player involvement there may be further delays whether they are warranted or not ...


..... Sandoz might throw us a bone after they lost in court against Sanofi but again IMO it won't be anything like the lofty price tags @antibotter and other optimistic posters on here believe it will be - just sayin'


There is also no 100% guarantee that the licensee will sail through the FDA 505 pathways easily for either of our DEP® drugs and of course I remain a little pessimistic given Starpharma continually claim that they are in confidential commercial discussions with several 'potential partners' year after year after year and not being able to deliver a single license deal in all that time (to date)



https://hotcopper.com.au/threads/up...s-for-dep-dci.7130434/page-2?post_id=65156425

My estimates:

DEP® Docetaxel
$NIL

DEP® Cabazitaxel
$10 million

DEP® Irinotecan
$25 million